Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study to Evaluate the Dose, Safety and Tolerability and Efficacy of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin®) in Subjects With Peritoneal Carcinomatosis From Colorectal Carcinoma Following Hyperthermic Intraperitoneal Chemotherapy

NCT03732781 is registered in ClinicalTrials.gov with Oncoinvent Solutions AS as lead sponsor.

NCT NCT03732781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03732781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study to Evaluate the Dose, Safety and Tolerability and Efficacy of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin®) in Subjects With Peritoneal Carcinomatosis From Colorectal Carcinoma Following Hyperthermic Intraperitoneal Chemotherapy
Lead sponsor
Oncoinvent Solutions AS
Phase
Phase 1/2
Overall status
Completed
Start date
May 27, 2020
Completion date
May 14, 2025
Enrollment
47 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma, peritoneal carcinoma